CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke a Korean nationwide cohort study

Tae Hoon Kim, Pil Sung Yang, Daehoon Kim, Hee Tae Yu, Jae Sun Uhm, Jong Youn Kim, huinam pak, Moon Hyoung Lee, Boyoung Joung, Gregory Y.H. Lip

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Purpose-As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort. Methods-From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013. Results-At baseline, the proportions categorized as low risk using CHADS2, CHA2DS2-VASc, and ATRIA risk stratification schemes were 1049 (17.9%), 860 (14.7%), and 3280 (56.0%), respectively. During follow-up, the low-risk category using CHADS2, CHA2DS2-VASc, and ATRIA scores was retained in 811 (13.9%), 667 (11.4%), and 2729 (46.6%) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS2, CHA2DS2-VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA2DS2-VASc had the best sensitivity (98.8% versus 85.7% in CHADS2 and 74.8% in ATRIA) and negative predictive value (98.8% versus 95.3% for CHADS2 and 93.7% for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95% confidence interval, 8.8-30.8]). Conclusions-The CHA2DS2-VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS2 and ATRIA scores.

Original languageEnglish
Pages (from-to)2984-2990
Number of pages7
JournalStroke
Volume48
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Atrial Fibrillation
Cohort Studies
Stroke
Anticoagulants
Transient Ischemic Attack
National Health Programs
Diabetes Mellitus
Heart Failure
Hypertension
Korea
Vascular Diseases
Odds Ratio
Databases
Confidence Intervals
Incidence

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialised Nursing

Cite this

Kim, T. H., Yang, P. S., Kim, D., Yu, H. T., Uhm, J. S., Kim, J. Y., ... Lip, G. Y. H. (2017). CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke a Korean nationwide cohort study. Stroke, 48(11), 2984-2990. https://doi.org/10.1161/STROKEAHA.117.018551
Kim, Tae Hoon ; Yang, Pil Sung ; Kim, Daehoon ; Yu, Hee Tae ; Uhm, Jae Sun ; Kim, Jong Youn ; pak, huinam ; Lee, Moon Hyoung ; Joung, Boyoung ; Lip, Gregory Y.H. / CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke a Korean nationwide cohort study. In: Stroke. 2017 ; Vol. 48, No. 11. pp. 2984-2990.
@article{179759b17a4642e8b9b0ef967cbfa0a5,
title = "CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke a Korean nationwide cohort study",
abstract = "Background and Purpose-As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort. Methods-From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013. Results-At baseline, the proportions categorized as low risk using CHADS2, CHA2DS2-VASc, and ATRIA risk stratification schemes were 1049 (17.9{\%}), 860 (14.7{\%}), and 3280 (56.0{\%}), respectively. During follow-up, the low-risk category using CHADS2, CHA2DS2-VASc, and ATRIA scores was retained in 811 (13.9{\%}), 667 (11.4{\%}), and 2729 (46.6{\%}) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS2, CHA2DS2-VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA2DS2-VASc had the best sensitivity (98.8{\%} versus 85.7{\%} in CHADS2 and 74.8{\%} in ATRIA) and negative predictive value (98.8{\%} versus 95.3{\%} for CHADS2 and 93.7{\%} for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95{\%} confidence interval, 8.8-30.8]). Conclusions-The CHA2DS2-VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS2 and ATRIA scores.",
author = "Kim, {Tae Hoon} and Yang, {Pil Sung} and Daehoon Kim and Yu, {Hee Tae} and Uhm, {Jae Sun} and Kim, {Jong Youn} and huinam pak and Lee, {Moon Hyoung} and Boyoung Joung and Lip, {Gregory Y.H.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1161/STROKEAHA.117.018551",
language = "English",
volume = "48",
pages = "2984--2990",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke a Korean nationwide cohort study. / Kim, Tae Hoon; Yang, Pil Sung; Kim, Daehoon; Yu, Hee Tae; Uhm, Jae Sun; Kim, Jong Youn; pak, huinam; Lee, Moon Hyoung; Joung, Boyoung; Lip, Gregory Y.H.

In: Stroke, Vol. 48, No. 11, 01.11.2017, p. 2984-2990.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke a Korean nationwide cohort study

AU - Kim, Tae Hoon

AU - Yang, Pil Sung

AU - Kim, Daehoon

AU - Yu, Hee Tae

AU - Uhm, Jae Sun

AU - Kim, Jong Youn

AU - pak, huinam

AU - Lee, Moon Hyoung

AU - Joung, Boyoung

AU - Lip, Gregory Y.H.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background and Purpose-As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort. Methods-From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013. Results-At baseline, the proportions categorized as low risk using CHADS2, CHA2DS2-VASc, and ATRIA risk stratification schemes were 1049 (17.9%), 860 (14.7%), and 3280 (56.0%), respectively. During follow-up, the low-risk category using CHADS2, CHA2DS2-VASc, and ATRIA scores was retained in 811 (13.9%), 667 (11.4%), and 2729 (46.6%) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS2, CHA2DS2-VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA2DS2-VASc had the best sensitivity (98.8% versus 85.7% in CHADS2 and 74.8% in ATRIA) and negative predictive value (98.8% versus 95.3% for CHADS2 and 93.7% for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95% confidence interval, 8.8-30.8]). Conclusions-The CHA2DS2-VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS2 and ATRIA scores.

AB - Background and Purpose-As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort. Methods-From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013. Results-At baseline, the proportions categorized as low risk using CHADS2, CHA2DS2-VASc, and ATRIA risk stratification schemes were 1049 (17.9%), 860 (14.7%), and 3280 (56.0%), respectively. During follow-up, the low-risk category using CHADS2, CHA2DS2-VASc, and ATRIA scores was retained in 811 (13.9%), 667 (11.4%), and 2729 (46.6%) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS2, CHA2DS2-VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA2DS2-VASc had the best sensitivity (98.8% versus 85.7% in CHADS2 and 74.8% in ATRIA) and negative predictive value (98.8% versus 95.3% for CHADS2 and 93.7% for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95% confidence interval, 8.8-30.8]). Conclusions-The CHA2DS2-VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS2 and ATRIA scores.

UR - http://www.scopus.com/inward/record.url?scp=85032158354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032158354&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.117.018551

DO - 10.1161/STROKEAHA.117.018551

M3 - Article

C2 - 28939672

AN - SCOPUS:85032158354

VL - 48

SP - 2984

EP - 2990

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 11

ER -